Cardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than conventional therapies, has revolutionized oncology therapy and dramatically changed cancer prognosis. However, some of these therapies have introduced an assortment of cardiovascular (CV) complications.
limitations of current nonclinical strategies in predicting cardiotoxicities.
Here, we discuss new insights on CV safety in the development of novel targeted anticancer drugs.
Successful and efficient drug development is predicated on establishing nonclinical models that can be high-throughput, cost-effective, and comparable to human physiology for the purposes of clinical efficacy and safety. In addition, these models must help in understanding mechanisms of CV toxicities and strategies for CV toxicity protection. We explore drug-induced cardiotoxicity testing strategies and review the existing nonclinical models (in vitro, in vivo, and in silico), which focus on identifying CV complications with high mortality risk such as sudden cardiac death secondary to arrhythmia and heart failure ( Figure 1 ). In particular, we highlight recent advances in human pluripotent stem cell-derived cardiomyocytes (PSC-CMs) as a revolutionary in vitro model that can improve cardiotoxicity assessment via personalized medicine and discuss the merits of in vivo and in silico models. Combining data from these respective methods will ensure a better translation to improving patient safety. Last, we conclude with a discussion of the clinical implications of monitoring and reducing CV toxicities gleaned from nonclinical studies.
THE EMERGENCE OF CARDIO-ONCOLOGY
Over the past several decades, improved understanding of the cellular and molecular biology underlying various types of cancer has led to rapid advancements in drug discovery and treatment efficacy. From 1991 to 2012, the overall cancer death rate declined by 23% (6) Table 1) . These adverse sequelae include acute and chronic CV toxicities and include a variety of complications such as cardiomyopathy, coronary and peripheral vascular disease, conduction abnormalities, thrombosis, hypertension, and metabolic disorders (4, 8) . However, because novel cancer drugs can revolutionize treatment and prolong life, cardiotoxicity risk must be carefully weighed against the overall benefit of cancer treatment.
Within the same class of "targeted" therapies, the CV toxicity can be complex. This is illustrated in the case of small molecular inhibitors targeting tyrosine kinase pathways (so-called TKIs or tyrosine kinase inhibitors), used for the treatment of chronic myeloid leukemia (CML). Imatinib, a first-in-class TKI targeting the ABL1 kinase, which is aberrantly activated in CML, revolutionized treatment by roughly doubling the 5-year survival rates of newly diagnosed CML to 89% (9) . Subsequently, second-(nilotinib, dasatinib, and bosutinib) and third-(ponatinib) generation TKIs were developed for CML treatment.
Initially, these TKIs were developed to overcome imatinib resistance, but given their greater potency against ABL1 kinase, they were positioned for front-line therapy in CML. However, while imatinib carries minimal CV risk, dasatinib is associated with pulmonary hypertension, and nilotinib is associated with hyperglycemia and vascular events (5) The experience with TKIs in CML generates several important issues that apply to all new cancer therapies. A TKI with a novel mechanism that demonstrates unprecedented activity in disease areas of highly unmet need has a benefit-to-risk acceptability profile that is different from the second-generation drug in that same class. As other drugs with similar mechanisms are developed for the same cancer type, it is expected that there will be an improvement in the safety profile. To achieve this goal, a more robust CV monitoring plan needs to be implemented during the nonclinical and early clinical trials of newer compounds of the same class ( Table 2) . Finally, understanding the mechanisms of CV toxicities that do 
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A U G U S T 2 0 1 6 : 3 8 6 -9 8 In cases where specific concerns of CV effects are present and the drug is being investigated in a patient population for whom clinical management of these CV toxicities may benefit from further characterization in nonclinical studies, a more comprehensive evaluation of hemodynamics and mechanical and electrical functions may be warranted.
In the following section, we discuss the established and emerging methods to examine potential cardiotoxic effects of cancer drugs ( Sheng et al.
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A U G U S T 2 0 1 6 : 3 8 6 - Pembrolizumab 2014 *Data from the U.S. FDA (100). Both boxed warnings and W and P sections of labeling for human prescription drugs are recommended by the FDA as industry guidance to categorize reporting of various adverse reactions. The boxed warnings highlight serious cardiotoxicities (fatal, life-threatening, or permanently disabling), adverse reactions that can be prevented or alleviated, or use with safety restrictions. In addition to the boxed warning, the W and P section describes a discrete set of cardiovascular adverse reactions that are serious or are otherwise clinically significant because they have implications for prescribing decisions or for patient management.
CHF ¼ congestive heart failure; DVT ¼ deep vein thrombosis; FDA ¼ Food and Drug Administration; HTN ¼ hypertension; MI ¼ myocardial infarction; NA ¼ not applicable; PAH ¼ pulmonary hypertension; PE ¼ pulmonary embolism; W and P ¼ warnings and precautions.
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A U G U S T 2 0 1 6 : 3 8 6 -9 8 be phenotyped for cardiotoxicity by several means, including cell death or indirectly, for example, by measuring cytosolic lactate dehydrogenase release into the medium (20) . While NRVMs are commercially available and maintain contractility in culture, a major caveat is that these cells can be overly sensitive to perturbations such as medium and experimental conditions. Also, it is unclear how much these cells recapitulate human cardiomyocytes. In general, the preparation and isolation of primary cells are time-consuming, costly, and technically difficult, as enzymatic digestion disrupts the cell membrane permeability for ion exchange (21) . In proof-of-principle investigations, PSC-CM studies detected the cardiotoxicity of drugs that are
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A U G U S T 2 0 1 6 : 3 8 6 - Zebrafish studies also detected drug-drug interactions leading to QT prolongation such as those between erythromycin and cisapride and between cimetidine and terfenadine. A more recent study in zebrafish discriminated between TKIs that caused cardiomyopathy (sunitinib and sorafenib) versus those that do not (gefitinib) (19) . The one caveat is that while the zebrafish kinome is very similar to that of human, subtle species differences in amino acid sequence could affect the binding interaction, thus leading to under-or over-estimation of toxicity (77) . Sheng et al.
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Cardiovascular Toxicity of Anticancer Drugs cancer treatment (92) . In the future, genetic screening may help to identify at-risk cardiotoxicity patients, as evidence by the fact that single nucleotide polymorphisms associated with protection from or susceptibility to anthracycline CV toxicity (93) (94) (95) .
Ultimately, well-designed epidemiologic studies from prospective trials will be essential to determine the true incidence, severity, and natural history of various CV toxicities.
Another emerging model to predict potential car- 
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